NCT05361395 2026-03-03First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)AmgenPhase 1 Active not recruiting184 enrolled
NCT02318277 2022-01-13A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)Incyte CorporationPhase 1/2 Completed176 enrolled 25 charts
NCT02586987 2019-11-18A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed58 enrolled
NCT02403271 2019-01-03A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsPharmacyclics LLC.Phase 1/2 Completed124 enrolled 17 charts